Correlation between hepatocyte growth factor receptor and vascular endothelial growth factor-A in breast carcinoma.

Iwona Gisterek, Rafał Matkowski, E Suder, Agnieszka Hałoń, Jolanta Szelachowska, Ewelina Łata, Aleksandra Łacko, Przemysław Biecek, Jan KornafelFolia 2010 · DOI

Abstract

This study evaluates the prognostic value of vascular endothelial growth factor A (VEGF-A) and hepatocyte growth factor receptor (HGFR, c-met) expressions in a homogenous group of 98 patients with Stage II invasive ductal breast carcinoma. While a strong biological correlation was observed between VEGF-A and c-met expression, neither marker correlated with clinical parameters (tumor size, grade, lymph node status) or long-term survival (5- and 10-year DFS/OS). The findings suggest that while these pathways are linked, they do not serve as independent prognostic indicators in this specific patient population.

Introduction

Identifying reliable biomarkers for Stage II breast cancer is a critical clinical challenge. While some patients require aggressive intervention, others may be overtreated. This study focuses on two key pathways: the Hepatocyte Growth Factor (HGF)/c-met axis, involved in cell proliferation, and Vascular Endothelial Growth Factor A (VEGF-A), a primary driver of angiogenesis. Given conflicting reports in existing literature, this research aims to clarify their prognostic utility within a strictly defined patient cohort.

Methods

The researchers analyzed archival tumor samples from 98 patients diagnosed with Stage II invasive ductal breast carcinoma at the Lower Silesian Oncology Center. All patients underwent primary surgery (modified radical mastectomy).

Protein expression was assessed using Immunohistochemistry (IHC). Staining intensity and prevalence were scored on a semi-quantitative scale from 0 to 3. For example, Level 2 indicated that 33–66% of cells were stained.

Representative IHC staining patterns for HGFR and VEGF-A in tumor tissue.

Statistical analysis included Pearson and Spearman rank correlations to evaluate the relationship between markers, and Kaplan-Meier curves with log-rank tests to assess 5-year and 10-year Disease-Free Survival (DFS) and Overall Survival (OS).

Results

The study found that both markers were frequently expressed in the tumor samples, with c-met positivity at 63% and VEGF-A positivity at 69%.

Distribution of HGFR and VEGF-A expression levels across the 98-patient cohort.

Biological Correlation

A statistically significant correlation was identified between c-met and VEGF-A expression (Pearson’s $p=0.0176$; Spearman’s $p=0.0205$). This supports the hypothesis of biological "crosstalk," where HGF/c-met signaling may stimulate VEGF-A production.

Clinical and Prognostic Outcomes

Despite the biological link, neither marker showed a significant association with:

  • Clinical parameters (age, tumor size, malignancy grade, or axillary lymph node status).
  • Long-term survival outcomes (no significant difference in 5-year or 10-year DFS or OS between high and low expression groups).

Discussion

The strong correlation between c-met and VEGF-A confirms their cooperative role in tumor biology, likely contributing to a pro-angiogenic environment. However, the lack of prognostic significance in this study contrasts with some previous findings. The authors attribute this to the homogeneity of their patient group. By focusing exclusively on Stage II ductal carcinoma, the study may have eliminated confounding variables present in more diverse cohorts, suggesting that these markers' prognostic value might be stage-dependent or more pronounced in heterogeneous populations.

Conclusion

While c-met and VEGF-A are biologically linked in breast cancer progression, they do not appear to be effective independent prognostic tools for Stage II invasive ductal carcinoma. Future research with larger, multi-center cohorts may be necessary to determine if these markers hold value when integrated into broader molecular profiling panels.

Summary updated

Abstract

The aim of the study was to evaluate the prognostic value of the vascular endothelial growth factor A (VEGF-A) and hepatocyte growth factor receptor (HGFR, c-met) expressions in homogenous group of breast cancer patients. Tumor samples were collected from 98 patients with invasive ductal breast carcinoma stage II treated with primary surgery. We have observed a strong correlation between VEGF-A and c-met. No correlations were found between VEGF-A or HGFR expressions and clinical parameters (tumor size, grade, axillary lymph node status, age), 5- and 10-years DFS or OS. Our study did not reveal any prognostic value of c-met or VEGF. In addition they are not useful to separate a patients' subgroup with poor prognosis. Unlike in other authors' studies, our patients' group is very homogenous which might tribute to obtained results.
BibTeX
@inproceedings{gisterek2010correlation,
  author = {Iwona Gisterek and Rafał Matkowski and E Suder and Agnieszka Hałoń and Jolanta Szelachowska and Ewelina Łata and Aleksandra Łacko and Przemysław Biecek and Jan Kornafel},
  title = {{Correlation between hepatocyte growth factor receptor and vascular endothelial growth factor-A in breast carcinoma.}},
  booktitle = {Folia},
  year = {2010},
  doi = {10.2478/v10042-010-0016-0},
}
Figure